Merck & Co. Inc. (NYSE:MRK) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 7:30 PM ET
Company Participants
Robert Davis – Chairman and CEO
Dean Li – Executive VP & President of Merck Research Laboratories
Conference Call Participants
Chris Schott – JPMorgan
Chris Schott
Good afternoon, everybody. I’m Chris Schott from JPMorgan, and it’s my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO; as well as Dean Li, who is the President of Merck Research Labs. So Rob and Dean, Happy New Year. Thanks for joining us. We look forward to our presentation from Rob and Dean, and then we’re going to jump into some Q&A from there. So with that…
Robert Davis
Thanks. Great. Good afternoon, everybody. Before we get started, I will point out that I will be making forward-looking statements. So if you would like to see our information on this, please see our website and you can get — learn more about what we do and we think about making forward statements, and obviously, they carry with them their own risks and uncertainties.
As you reflect on where Merck is and where we’ve been, hopefully, you see what we see. And I can tell you, I feel very good about where the team is in executing on our strategic priorities. And if I think about that, most importantly, it’s the progress we’re making, advancing the pipeline and augmenting the pipeline. And importantly, we continue to focus on scientific innovation with the patient really at the center as the core of what we see as a driver of long-term sustainable value, both for our shareholders and for all of our stakeholders.
We’re now at a little over 3.5 years since I took over the role of CEO and
